Articles tagged "Kidney transplantation"

2016 American Transplant Congress
Mechanisms of Cellular Repopulation within Healthy or Intrinsically Scarred Kidney Extracellular Matrix Scaffolds.
J. Uzarski,¹ C. Deaton,⁵ H. Ward,² A. Wandinger-Ness,³ W. Miller,⁴ J. Wertheim.¹
¹Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL; ²Department of Internal Medicine, University of New Mexico HSC, Albuquerque, NM; ³Department of Pathology, University of New Mexico HSC, Albuquerque, NM; ⁴Department of Chemical and Biological Engineering, Northwestern University, Evanston, IL; ⁵Department of Biology, University of Mexico, Albuquerque, NM.
Background: While the number of wait-listed patients suffering from kidney failure continues to rise, the number of kidney transplants performed each year has remained stagnant.…
2016 American Transplant Congress
Increased Incidence of Clostridium difficile Infections with Proton Pump Inhibitor Use Post-Kidney Transplant.
M. Spinner,¹ K. Patel,¹ E. Neuner,¹ B. Stephany.²
¹Department of Pharmacy, Cleveland Clinic, Cleveland, OH; ²Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, OH.
Clostridium difficile infection (CDI) is often encountered in the solid-organ transplant patient population. The incidence in kidney transplant recipients ranges between 3.5-16%. There are CDI…
2016 American Transplant Congress
Two-Year Safety Results from the Phase 3b Switching Study of Kidney Transplant Patients with Tremor to LCP-Tacro (STRATO) Study.
S. Steinberg,¹ R. Gedaly,² L. Chan,³ A. Langone.⁴
¹California Institute of Renal Research, San Diego; ²University of Kentucky Medical Center, Lexington; ³University of Colorado, Aurora; ⁴Vanderbilt University Medical Center, Nashville.
Tremor is a common side effect of tacrolimus (tac) correlated with peak-dose drug concentration. Envarsus XR®, a novel, once-daily, extended-release formulation of tac, has a…
2016 American Transplant Congress
Geographic Variability in Access to Transplant Centers for Children with End-Stage Renal Disease.
C. Toro,¹ M. Ross,^1,2 D. Wiebe,² S. Amaral.^1,2
¹Pediatrics, The Children's Hospital of Phila, Philadelphia, PA; ²Biostatistics and Epidemiology, The University of Pennsylvania, Philadelphia, PA.
Background: Kidney transplantation is the optimal treatment for pediatric end-stage renal disease (ESRD); yet, there is substantial variability in waiting times for deceased donor kidneys…
2016 American Transplant Congress
De Novo Proliferative Glomerulonephritis with Monoclonal IgG Deposits of the IgG1κ Subtype in a Kidney Allograft: Protocol Biopsy Findings.
T. Tsuji,¹ M. Miura,² M. Yanai,¹ H. Itami,¹ Y. Ishii,¹ M. Akimoto,¹ Y. Fukasawa.¹
¹Department of Pathology, Sapporo City General Hospital, Sapporo, Japan; ²Departments of Renal Transplant Surgery and Urology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Proliferative glomerulonephritis with monoclonal immunoglobulin G (IgG) deposits (PGNMID) has recently been described in cases with glomerular disease. Only a dozen cases of recurrent or…
2016 American Transplant Congress
Urinary Virome in Human Kidney Transplants Reveals Multiple Virus Subtypes with Distinct Genome Polymorphisms.
R. Ranjan,¹ A. Rani,¹ H. McGee,¹ D. Brennan,² P. Finn,¹ D. Perkins.^1,3
¹Medicine, University of Illinois, Chicago, IL; ²Division of Renal Diseases, Washington University School of Medicine, St. Louis, MO; ³Surgery, University of Illinois, Chicago, IL.
Recent studies have established that human urine has its own unique microbiome, but little is known about the virome. The human virome is the collection…
2016 American Transplant Congress
Concomitant Proton Pump Inhibitor and Mycophenolate Mofetil Use in Renal Transplant Recipients.
K. Patel,¹ B. Stephany,² J. Barnes,¹ S. Bauer,¹ M. Spinner.¹
¹Department of Pharmacy, Cleveland Clinic, Cleveland, OH; ²Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, OH.
Pharmacokinetic (PK) data show reduced mycophenolic acid levels in transplant recipients taking mycophenolate mofetil (MMF) and proton pump inhibitors (PPIs) concomitantly. MMF dosing is not…
2016 American Transplant Congress
Pulse Wave Velocity Amongst African-American Kidney Transplant Recipients Randomized to Once-Daily MeltDose Tacrolimus Tablets (Envarsus XR) vs. Traditional Twice-Daily Tacrolimus Capsules: Exploratory Results from a Phase III Trial.
J. Trofe-Clark,^1,2 R. Townsend,² R. Neubauer,² M. Lim,² L. Callahan,³ R. Bloom.²
¹Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, PA; ²Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; ³Veloxis Pharmaceuticals, Edison, NJ.
Cardiovascular (CV) death is a leading cause of death in kidney transplant recipients (KTR). Increased aortic arterial stiffness is strongly associated with the development of…
2016 American Transplant Congress
HLA Class II and BK Virus Reactivation in Renal Transplant Recipients.
P. Shah,¹ K. Anderson,² M. Aubrey,² C. Roark,² B. Freed,² A. Wiseman.¹
¹Division of Renal Diseases and Hypertension, University of Colorado School of Medicine, Aurora, CO; ²Division of Immunology, University of Colorado School of Medicine, Aurora, CO.
BK Viremia (BKV) and subsequent BK nephropathy are associated with renal graft loss. The Human Leukocyte Antigen (HLA) region has been implicated in susceptibility to…
2016 American Transplant Congress
Variation in Co-Medication Use According to Kidney Transplant Immunosuppressive Regimen: Application of Integrated Registry and Pharmacy Claims Data.
K. Lentine,¹ A. Naik,² M. Schnitzler,¹ D. Axelrod,³ J. Chen,¹ D. Brennan,⁴ D. Segev,⁵ B. Kasiske,⁶ H. Randall,¹ V. Dharnidharka.⁴
¹Saint Louis Univ, St. Louis; ²Univ Michigan, Detroit; ³Dartmouth Univ, Hanover; ⁴Washington Univ, St. Louis; ⁵Johns Hopkins Univ, Baltimore; ⁶Univ Minnesota, Minneapolis.
Background: While modern immunosuppressive therapies (ISx) have substantially reduced acute rejection, ISx medications have many side effects, and transplant recipients must take an array of…